Prof. Abubakar Yaro, the Scientist, and His Compass: Bridging Molecular Rigor and Global Compassion

The morning air in the research wing of the AHRO Center for Academic Research is filled with anticipation, and the hum of high-speed sequencers and the steady pulse of multiomics platforms. Prof. Abubakar Yaro, as the Director General and Chief Scientific Officer, stands before a digital display of molecular structures, his eyes tracking the path of a small drug molecule as it interacts with a viral protein. For a scientist who has spent decades studying the mechanics of infection, this moment is the culmination of a journey that began in the clinical pathology labs of Ghana and moved through the specialized Laboratory of the Royal Free Hospital in London as an intern.

The Duality of Modern Leadership

Leadership today isn’t just about authority or vision—it’s about navigating complexity with clarity while staying grounded in evidence and human realities, he feels. From his perspective, leadership means making high-stakes decisions under uncertainty, aligning diverse teams across cultures, and delivering sustainable value. From his perspective as a scientist, leadership is rooted in curiosity, rigor, and intellectual honesty. It means forming hypotheses, testing assumptions, and being willing to update one’s beliefs when new data emerges. In today’s world, that mindset is critical—because many decisions regarding AI, public health, and energy sit at the intersection of science, policy, and business.

Prof. Abubakar’s leadership as the DG is defined by a rare combination of clinical precision and humanitarian drive. With a background that spans a Doctorate in Science in Emerging Infectious Diseases and a PhD in Clinical Microbiology, Prof. Abubakar does not just manage an organization. He lives within the science. From his early days at Vis Viva Pharma Ltd, as its CEO & President, leading lead identification, to his current role overseeing Dr. Yaro Laboratory Ltd, as the Chief Scientific Officer, along with being Editor-in-Chief for Annals of Clinical Medicine and Public Health, he has remained focused on the fundamental question of how the human immune system reacts to the presence of disease. He looks at the dysregulation of the body not just as a medical problem, but as a puzzle that requires both molecular techniques and bioinformatics to solve.

Bridging Scientific Rigor and Executive Strategy

Prof. Abubakar knows that balancing scientific rigor with strategic leadership responsibilities at the executive level is crucial. He is so passionate about doing science. However, because he is also needed to play a leadership role, he has adopted certain strategies to enable him balance the science done at his institute with his responsibilities at the executive level. He normally separates “standards” from “participation,” which means he doesn’t need to be in every analysis—but he does need to define what “good science” looks like to those who work with him.

The global community recognizes him as a scholar who bridges the gap between the laboratory and the library. As the coordinator of the Global Public Health Thinkers Group, he facilitates the exchange of ideas that eventually become the scientific texts used to train the next generation. He

has authored over eight scientific books, including pivotal works on coronaviruses and oncoviruses, and yet he still finds the time to write on matters of faith and humanity. This duality defines his approach. He understands that while science can develop an anti-infective drug, it takes a humanitarian spirit to ensure that the drug reaches the people who need it most.

Defining Non-Negotiable Standards

So, in the scientific activities that require rigor, he sets non-negotiable standards: study design, data quality, reproducibility, and ethics. He requires structured outputs that answer specific questions: What was the question? What did the data show? How confident are we? What decision does this support? In addition, instead of being involved throughout the research processes, he normally inserts himself at critical inflection points such as problem definition, study approval, and pre-decision evidence review.

The Power of Institutional Challenge

In his institute, heads of research departments are empowered to challenge him. He hates being in charge from the start to the end. He believes that without someone challenging him on the interpretation of data, the rigor of science will erode.

In the laboratory, the focus is now on the identification of biomarkers and the development of new tools to combat antimicrobial resistance. Prof. Abubakar moves between benches, offering guidance to junior researchers with the same patience he uses when chairing monthly lectures for international thinkers. He emphasizes the importance of understanding the pathogenesis of infectious diseases as the benchmark for all their work. Under his guidance, the AHRO Center has become a beacon for small drug molecule initiatives, pushing the boundaries of how both infection and cancer are treated.

The Multiomics Revolution: A Systems-Level Vision

Prof. Abubakar is really excited about multiomics technology because it is transforming infectious disease research at a rapid rate, since it stops scientists from looking at pathogens through a single keyhole and instead gives a systems-level view of the interaction between pathogen, host, and environment. At its core, multiomics integrates multiple biological data layers such as genomics, transcriptomics, proteomics, metabolomics, epigenomics, and microbiomics. This matters in infectious diseases because pathogens rarely act alone; disease severity is shaped by host immunity, metabolism, microbiome composition, and even environmental exposures.

Therefore, he believes multiomics can lead to more precise pathogen discovery and characterization, facilitate personalized infectious disease medicine, facilitate faster biomarker discovery and diagnostics, improve vaccine development and immune profiling, help in AMR intelligence, which can play a significant role in addressing the AMR menace, and play a significant role in one health and outbreak prediction. Although multiomics technology is promising, he acknowledges that some challenges must be addressed, such as data integration complexity, standardization issues, and ethical or data governance concerns. Multiomics

technology is utilized immensely in his lab, so he and his team hope to address some of these challenges.

Confronting the “Slow Pandemic” of Antimicrobial Resistance

With antimicrobial resistance (AMR) rising globally, he asserts that the urgent priorities are not mysterious—we already know many of them. The challenge is execution at scale, coordination, and political commitment. AMR is sometimes described as a “slow pandemic,” which is unfortunately accurate: less dramatic than an outbreak, but potentially devastating over time. What he argues we need to prioritize is strengthening antimicrobial stewardship with important actions such as enforced prescription-only antibiotic policies, creating treatment guidelines based on local resistance data, and monitoring antibiotic consumption nationally.

This is especially critical because antibiotics are still overused for viral illnesses, empirical treatment, and prolonged prophylaxis. He advocates for a focus on expanding rapid diagnostics with institutions prioritizing investing in molecular testing and diagnostic stewardship. The faster clinicians can distinguish bacterial from viral infection—or identify resistance patterns—the less likely they are to prescribe broad-spectrum therapy blindly. He notes the need for a national AMR surveillance system where alignment with frameworks from the World Health Organization Global Antimicrobial Resistance and Use Surveillance System is often valuable.

A One Health Approach to Global Security

Prof. Abubakar insists we must regulate antimicrobial use in agriculture and animal health, as this is a core One Health issue. We need to improve infection prevention and control, and incentivize antimicrobial R & D. He also points to the need for investment in workforce training and an urgent need for public awareness and behavior change. Governance and accountability should be strengthened while prioritizing AMR in global health financing and diplomacy. He believes every hand should be on the deck because the window period is closing and humanity is at a crossroads!

The Critical Link: Academia, Industry, and Policy Collaboration

Collaboration between academia, industry, and policymakers is not just helpful in global health crises—it is often the difference between fragmented effort and coordinated impact. From his perspective, each sector solves a different part of the puzzle, and when they operate in silos, progress slows exactly when speed matters most. He recognizes that academia generates evidence and scientific discovery, while industry converts the discoveries into scalable products, and policymakers create enabling systems and public health coordination.

As experienced during COVID-19, a common problem in global health is the “valley of death” between discovery and implementation. This means collaboration reduces the translation gap. Without collaboration, academia may produce evidence with limited real-world uptake, industry may develop products misaligned with public needs, and policymakers may make decisions without strong evidence. However, he notes that collaboration can reduce these disconnects by aligning: research priorities, product development, regulatory pathways, and implementation strategies.

Lessons for Future Crisis Response

Collaboration can lead to accelerated crisis response. One of the biggest lessons Prof. Abubakar learned from the COVID-19 crisis was that innovation without equitable distribution creates global vulnerability. Therefore, cross-sector collaboration is required for tiered pricing, pooled procurement, manufacturing partnerships, technology transfer, and regional production hubs. He observes that organizations such as the World Health Organization, Gavi, the Vaccine Alliance, and Coalition for Epidemic Preparedness Innovations often sit at these intersections.

He also notes that the best collaborations are built before emergencies, with long-term partnerships able to support surveillance networks, pathogen libraries, trial platforms, manufacturing readiness, regulatory harmonization, and workforce development. Ultimately, he sees that collaboration can mobilize resources at a large scale.

The Tragic Catalyst: From Personal Loss to Global Mission

As is well known, a career path from clinical pathology to global research is often shaped by a single dramatic turning point and more by a series of decisions that gradually widen one’s lens. In the case of Prof. Abubakar, he experienced several such pivotal moments, but three really shaped his career pathway. His were tragic moments. First was the day his beloved mother held his hands and told him, “I will make sure you become a global scientist,” and a week later, she went missing. The pain of losing such a wonderful human being was so intense that it became his source of motivation whenever he faced difficult moments. His focus was to fulfill her dream of her son becoming a global scientist whose domain is beyond research, but leading global health.

The second was the deaths of his two senior sisters, Maryam and Abiba. At that moment, he was struggling to build AHRO instead of working. When they became sick, and he was asked for funds to take them to hospitals, he didn’t have them, and they died deaths that could have been prevented. That pain of losing his caring sisters really inspired his career path. These losses not only inspired him, but they turned him into a working machine!

The Transformation of Scientific Publishing

Scientific publishing is likely to change more in the next decade than it has in several previous ones combined. The traditional model—submit, wait months, revise repeatedly, publish behind a paywall, and hope the right people find it—is under increasing pressure from technology, open science expectations, and demand for faster knowledge translation. Issues like Open science will become harder to ignore. Prof. Abubakar expects to see preprints and rapid dissemination becoming standardized, while peer review should become more transparent and technology-assisted.

AI has the potential to transform writing, editing, and discoverability, but he asserts that we must regulate the use of AI in academic writing, as solely relying on AI would cause academics to become lazy. Future publishing will likely include dynamic outputs such as interactive figures, live datasets, video abstracts, and linked protocols. Articles may become more like research hubs than static documents. Impact metrics will evolve beyond the journal impact factor, with more

attention shifting towards article-level metrics, clinical guideline influence, dataset reuse, and social as well as implementation impact.

Strengthening Integrity and Global Equity

He also expects to see publishing ethics and integrity systems tightening. Publishing ethics and integrity systems should be tightened to take care of concerns around predatory journals and image manipulations. He expects to see growth in automated integrity screening, contributor verification, and ORCID-linked accountability systems through ORCID. There should be greater inclusion of global South scholarship, where geographic inequities in publishing should be addressed.

Reforms are required for fairer APC models, editorial diversity, regional indexing support, and mentorship for emerging researchers, especially those from developing countries. Scientific publishing cannot claim global importance while structurally underrepresenting large parts of the world. This is especially important in infectious diseases, public health, and implementation science, where locally generated evidence is often essential.

The Convergence of Science and Technology in 2026

In 2026, the breakthrough areas Prof. Abubakar is most excited about across virology, infectious diseases, and drug development are the ones where technologies are finally converging rather than advancing in isolation.

First, he notes that AI-driven drug discovery is moving from hype to actual translational value. This involves not just predicting protein structures after DeepMind and AlphaFold changed the game, but using multimodal AI to identify antiviral candidates, optimize molecules, predict toxicity, and shorten preclinical timelines. For him, the interesting shift is from “can AI design molecules?” to “can AI design molecules that survive the brutal realities of biology, manufacturing, and regulation?” That’s where 2026 gets exciting.

Broad Protection and Next-Generation Therapeutics

Second, he highlights the promise of universal or broadly protective vaccines. Instead of chasing each viral variant like a cat chasing laser dots, researchers are targeting conserved viral regions. For influenza, pan-influenza vaccines are progressing, and similar thinking is being applied to coronaviruses and emerging hemorrhagic viruses. He believes a truly broad coronavirus vaccine would be one of the decade’s most consequential breakthroughs.

Third, he sees potential in next-generation antivirals beyond classic small molecules. He observes an increasing interest in host-directed therapies, RNA therapeutics (including siRNA), and CRISPR-based antimicrobials. This matters to him because resistance is undefeated when we rely on single-mechanism drugs forever.

Intelligence Systems and Predictive Public Health

Fourth, he points to pathogen surveillance and outbreak intelligence. Wastewater genomics, portable sequencing, and real-time phylogenetics are making outbreaks visible earlier. Platforms

built on tools from outbreaks like COVID-19 and genomic surveillance ecosystems are now being adapted for antimicrobial resistance, zoonotic spillovers, and regional epidemic intelligence. In practice, he believes this could shift public health from reactive to genuinely predictive.

Fifth, he focuses on antimicrobial resistance (AMR) therapeutics. Though not glamorous, he considers it the most underappreciated battlefield, watching developments in bacteriophage therapies, anti-virulence drugs, microbiome engineering, and narrow-spectrum antibiotics guided by rapid diagnostics.

One Health and a Lasting Institutional Legacy

Sixth, Prof. Abubakar emphasizes One Health integration. The future of infectious disease control is less about isolated hospitals and more about linking human, animal, and environmental surveillance. Spillover prediction models, climate-linked vector forecasting, and zoonotic intelligence systems could become standard infrastructure rather than academic side projects.

The legacy he wants to leave behind as one of the most admired CEOs in the healthcare and research ecosystem is to build an institution that outlasts personality-driven leadership. He wants the future generation to remember him for his passion, sacrifice, and commitment to academics and health research.